Novartis Ag (NVSEF) Cash & Equivalents Growth (5y) (2014 - 2025)

Novartis Ag (NVSEF) Cash & Equivalents Growth (5y) (2014 - 2025) Analysis & Trends

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Novartis Ag	-	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2025	-23.21%
Jun 30, 2025	145.72%
Dec 31, 2024	-53.48%
Jun 30, 2024	-4.58%
Mar 31, 2024	-36.88%
Dec 31, 2023	0.18%
Jun 30, 2023	-2.64%
Dec 31, 2022	-3.23%
Dec 31, 2021	12.11%
Dec 31, 2020	15.62%
Jun 30, 2020	-14.87%
Mar 31, 2020	-87.96%
Dec 31, 2019	24,234.15%
Jun 30, 2019	3,351.40%
Dec 31, 2018	6,576.99%
Dec 31, 2017	9.80%
Dec 31, 2016	13.57%
Dec 31, 2015	-2.55%
Mar 31, 2015	-83.54%
Dec 31, 2014	-99.46%